Danish Trade Distributors Stock News

Regulatory milestone and why it matters for ALK-Abelló ALK-Abelló (CPSE:ALK B) is in focus after the European Medicines Agency’s CHMP issued a positive opinion supporting an extension of EURneffy’s marketing authorisation to include a 1 mg nasal adrenaline spray for children. This regulatory step, if converted into full European Commission approval, could broaden EURneffy’s eligible patient group across the EU, Iceland, Liechtenstein and Norway, giving investors another reference point when...

Genmab (CPSE:GMAB) is back on investors’ radar after recent share price swings, with the stock showing a 0.3% move over the past day but negative returns over the past month and past 3 months. See our latest analysis for Genmab. That recent 7 day share price return of 7.6% decline and 30 day share price return of 11.2% decline sit against a 1 year total shareholder return of 41.2%. This suggests near term momentum has cooled after a strong longer term run. If Genmab’s moves have you thinking...

With its stock down 20% over the past month, it is easy to disregard Dataproces Group (CPH:DATA). However, the...

GN Store Nord (CPSE:GN) has drawn fresh attention after reporting full year 2025 earnings, with sales of DKK 16,782 million and net income of DKK 653 million, both lower than the previous year. See our latest analysis for GN Store Nord. The latest full year earnings release appears to have weighed on sentiment, with the share price at DKK98.7 after a 7 day share price return of 8.14% and a 30 day share price return of 11.91%. However, the 1 year total shareholder return of 30.91% and 5 year...

A.P. Møller - Mærsk (CPSE:MAERSK B) has announced a significant annual dividend decrease following its full year 2025 earnings report. The dividend reduction comes alongside reported declines in net income and earnings for 2025. The change marks a shift in the company’s capital return approach shortly after weaker annual financial results. A.P. Møller Mærsk, trading as CPSE:MAERSK B, is adjusting its dividend policy at a time when its shares are at DKK15,250.0 and have returned 35.6% over...

NKT (CPSE:NKT) is back in focus after agreeing an exclusive long-term partnership with German grid operator Mainova, securing a cable supply role in Frankfurt’s power grid upgrade through 2033. See our latest analysis for NKT. Those headlines around Frankfurt’s grid upgrade and the new power purchase agreement with Uniper come on top of a 90 day share price return of 16.67% and a 1 year total shareholder return of 75.15%, signalling momentum that investors are watching closely beyond the...

Vestas Wind Systems (CPSE:VWS) just reported its fourth quarter and full year 2025 results, released new 2026 guidance, and paired that with a proposed dividend, a completed buyback, and fresh order intake. See our latest analysis for Vestas Wind Systems. The earnings release, fresh 2026 guidance, completed buyback and new Kapuni order come after a weak 7 day share price return of 16.55% decline and a year to date share price return of 7.86% decline. However, the 1 year total shareholder...

Novozymes is drawing fresh attention in Synthetic Biology and Bioprocessing as governments and global investors increase funding for the sector. The company is emerging as a key player in high throughput microbial engineering and precision fermentation, with growing relevance for industrial customers. These developments highlight new areas of potential long term importance for Novozymes within a future oriented segment of the bioindustry. For investors watching CPSE:NSIS B, the interest...

Novo Nordisk has intensified legal and regulatory efforts to protect its GLP-1 weight loss drugs from compounded copycat versions. Hims & Hers has withdrawn its oral semaglutide product after Novo Nordisk issued legal threats and announced a patent infringement lawsuit. The FDA has publicly committed to tighter action against unapproved compounded GLP-1 medications, affecting competing offerings across the sector. For investors watching CPSE:NOVO B, this dispute is about more than...

In early February 2026, Coloplast A/S reported first-quarter 2025-2026 results showing sales of DKK 7,043 million and net income of DKK 1,397 million, alongside updated guidance for around 7% EBIT growth in constant currencies for the fiscal year. The combination of modest sales movement but higher earnings per share suggests improved profitability, which can influence how investors assess Coloplast’s operational efficiency and earnings quality. Next, we’ll examine how Coloplast’s focus on...

As European markets remain buoyant, with the STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy prevailing, investors are keenly observing potential opportunities amid recent market volatility. In this context, identifying stocks that may be undervalued relative to their intrinsic worth can be a strategic approach for those looking to capitalize on market conditions where cyclical and value-oriented segments are gaining traction.

As the pan-European STOXX Europe 600 Index reaches new highs, optimism about the eurozone economy is helping to counterbalance recent market volatility. With inflation slowing faster than forecast and key interest rates remaining steady, investors are increasingly focusing on small-cap stocks that may offer unique opportunities in this evolving landscape. Identifying promising stocks often involves looking for companies with strong fundamentals and potential growth catalysts that align well...

FLSmidth & Co. A/S ( CPH:FLS ) shareholders have had their patience rewarded with a 25% share price jump in the last...

Danske Bank A/S' ( CPH:DANSKE ) dividend will be increasing from last year's payment of the same period to DKK22.72 on...

Tryg (CPSE:TRYG) has drawn fresh attention after its Board approved a share buyback programme of up to DKK 1.0b, running until 13 May 2026, with treasury holdings now at 11,308,326 shares. See our latest analysis for Tryg. At a share price of DKK155.0, Tryg has had a softer patch recently, with a 30 day share price return of 2.64% decline and a year to date share price return of 6.12% decline, even as the 1 year total shareholder return sits at 9.82%. This suggests longer term holders have...

It's been a mediocre week for Vestas Wind Systems A/S ( CPH:VWS ) shareholders, with the stock dropping 15% to kr.165...

Ringkjøbing Landbobank (CPSE:RILBA) has given investors a lot to digest by combining its full year 2025 results, a new 40% profit distribution policy and proposed changes to its capital authorisations and share capital. See our latest analysis for Ringkjøbing Landbobank. These announcements land after a strong run in the share price, with a 30 day share price return of 9.99% and a 1 year total shareholder return of 51.35%. This suggests positive momentum has been building around Ringkjøbing...

Shareholders might have noticed that A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) filed its yearly result this time last...

Pandora A/S ( CPH:PNDORA ) has announced that it will be increasing its dividend from last year's comparable payment on...

Gyldendal A/S' ( CPH:GYLD B ) investors are due to receive a payment of DKK20.00 per share on 21st of April. The...

Vestas Wind Systems (CPSE:VWS) has secured an order for the Kapuni Wind Farm in New Zealand. The project is one of New Zealand's first large-scale efforts to pair wind power with green hydrogen production. Kapuni is intended to support New Zealand's broader decarbonisation and renewable energy objectives. Kapuni adds another reference project to Vestas' core business in wind turbines and related services, while also highlighting its role in early green hydrogen projects. For you as an...

Coloplast Q1 2026 Earnings Snapshot Coloplast (CPSE:COLO B) opened its 2026 financial year with Q1 revenue of DKK 7.0b and basic EPS of DKK 6.21, alongside trailing twelve month EPS of DKK 17.70 and net income of DKK 4.0b. Over recent quarters the company has seen quarterly revenue move in a tight band between DKK 6.9b and DKK 7.0b, while quarterly EPS has ranged from DKK 3.57 to DKK 6.21 as net income shifted between DKK 805m and DKK 1.40b. This sets up this report as a check-in on how much...

The board of Novo Nordisk A/S ( CPH:NOVO B ) has announced that it will be paying its dividend of DKK7.95 on the 31st...

Last week saw the newest third-quarter earnings release from Matas A/S ( CPH:MATAS ), an important milestone in the...